Zetia (Ezetimibe) Antitrust v. Merck & Company, Inc.
Case Number:
20-2184
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
January 11, 2022
40 May Not Be The Magic Number To Certify A Wage Class
A year after the Seventh Circuit ruled that fewer than 40 workers in an overtime suit may be enough for class certification, attorneys told Law360 the decision highlights other factors to consider when assessing whether a class action meets a key requirement in a category called numerosity.
-
August 04, 2021
Zetia Judge Must Rethink 'Faulty' Class Cert., 4th Circ. Says
A Fourth Circuit panel hit the reset button Wednesday on the certification of a class of 35 drug wholesalers suing Merck and Glenmark for allegedly delaying generic entry of Merck cholesterol drug Zetia, remanding the antitrust case so a Virginia federal judge can reconsider her "faulty logic."
-
May 06, 2021
4th Circ. Mulls 'Murky' Law Around Small Zetia Buyer Class
The Fourth Circuit was chatty Thursday while mulling whether to uphold or overturn the certification of what pharmaceutical giants Merck and Glenmark have called an "extremely small" class of drug buyers in a fight over the delayed release of a cholesterol drug.
-
April 08, 2021
9th Circ. 'Directly Supports' Zetia Class Fight, 4th Circ. Told
Merck and Glenmark have told the Fourth Circuit that a newly issued Ninth Circuit decision upending class certification for buyers alleging price-fixing of canned tuna "directly supports" undoing certification of drug wholesalers accusing the two drugmakers of blocking a generic form of cholesterol drug Zetia.
-
January 05, 2021
Merck, Glenmark Fight Zetia Class Cert. At 4th Circ.
Drugmakers Merck and Glenmark have asked the Fourth Circuit to reverse the class certification of direct buyers of cholesterol drug Zetia, stating the named plaintiffs were unfit to represent the class and the other members' circumstances did not warrant class status.
-
November 16, 2020
4th Circ. Will Fast-Track Challenge To Zetia Buyers' Class Cert.
Direct buyers of Zetia got their wish granted Monday when the Fourth Circuit agreed to speed along a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of blocking a generic form of the cholesterol drug from making it to market.
-
November 12, 2020
Zetia Buyers Seek To Speed Up Drug Cos.' Class Cert. Appeal
In a bid to minimize delays, direct buyers of Zetia have urged the Fourth Circuit to expedite a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of violating antitrust law by blocking a generic form of the cholesterol medication.
-
November 03, 2020
4th Circ. Says OK To Zetia Class Certification Challenge
The Fourth Circuit is going to hear a challenge mounted by pharmaceutical giants Merck and Glenmark to the certification of what they have called an "extremely small" class of drug buyers alleging the duo conspired to keep a generic version of the cholesterol drug Zetia off the market.